Andere Sprachen StemRIM

Aktien

A2PNS8

JP3399690001

4599

Markt geschlossen - Japan Exchange Andere Börsenplätze 08:00:00 31.05.2024			% 5 Tage	% 1. Jan.
463 ^JPY	+3,12 %		+2,43 %	-19,90 %

13.03.	StemRIM kündigt Beginn einer klinischen Phase 2-Studie für Redasemtide bei ischämischer Kardiomyopathie an	CI
31.01.	StemRIM Inc. meldet Patentregistrierung (Russland) für die Verwendung des HMGB1-Fragmentpeptids als zusätzliche therapeutische Indikation bei Knorpelerkrankungen	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy	13.03.
StemRIM Inc. Announces Patent Registration for the Use of the HMGB1 Fragment Peptide, as an Additional Therapeutic Indication of Cartilage Disorders	31.01.
StemRIM Allocates 300 Stock Options to R&D Partner	29.12.
StemRIM Enters into Contract for Implementation of Phase 2 Investigator-Initiated Clinical Trial Targeting Ischemic Cardiomyopathy Using Redasemtide, in Collaboration with Osaka University Hospital and Shionogi & Co	04.12.
StemRIM, Shiseido, Osaka University Extend Skin Aging Research Collaboration	17.11.
Stemrim Inc. Announces Patent Registration (Us) for the Use of the Hmgb1 Fragment Peptide, Redasemtide	06.09.23
StemRIM Announces Patent Registration for the Use of Redasemtide as an Additional Treatment for Cardiomyopathy and Old Myocardial Infarction	04.09.23
StemRIM Inc. Announces the First Administration of Global Late Phase 2 Clinical Trials for Redasemtide Targeting Acute Ischemic Stroke	31.07.23
StemRIM Inc. Announces Commencement of Global Late Phase 2 Clinical Trial for Redasemtide in Patients with Acute Ischemic Stroke in the Europe and China	25.07.23
StemRIM Inc. Announces Patent Registration for the Use of the Hmgb1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction	18.07.23
StemRIM Provides Earnings Guidance for the Year Ending July 31, 2023	19.06.23
StemRIM Inc. Announces Publication of Scientific Articles for Stem Cell Gene Therapy	16.05.23
StemRIM Announces Milestone Achievement in Development of Therapeutic Drug (Redasemtide) Targeting Acute Ischemic Stroke	28.04.23
StemRIM Bags 450 Million Yen Milestone Payment From Shionogi; Details FY23 Earnings Outlook, Liver Disease Trial Results	12.04.23
Stemrim Inc. Announces Commencement of Global Phase II Trial of Redasemtide in Patients with Acute Ischemic Stroke	11.04.23
Toyo Suisan Kaisha, Ltd. Revises Earnings Guidance for the Year 2023	11.04.23
StemRIM Announces Earnings Results for the Quarter Ended October 31, 2019; Provides Earnings Guidance for the Full Year Ending July 31, 2020	12.12.19

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Alle Transkripte zu über 9000 Unternehmen - am Tag ihrer Veröffentlichung!

Jetzt freischalten!

fermer